Researchers suggest maintaining disease remission in people with lupus, especially during a pandemic infection, is extremely important to avoid unnecessary office and emergency room visits, and hospitalizations, all of which increase potential exposure to COVID-19. People with lupus should continue to take their immunosuppressive medications as they did before the pandemic. Avoid discontinuing or lowering doses of any immunosuppressive medication, unless suggested by your doctor.
There are characteristics of lupus that may result in more severe disease presentations, possibly resulting in a greater strain on the healthcare system and amplified virus exposure.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.
